OA

New Mountain Capital and Grant Thornton close growth investment

Retrieved on: 
Freitag, Mai 31, 2024
Finance, Consulting, Accounting, Professional Services, Asset Management, CFO, Investment, CDPQ, CPA, OA, Jefferies Group, Growth, Guggenheim Partners, LLP, Gibson Dunn, Dechert, Simpson Thacher & Bartlett

Grant Thornton LLP, one of America’s leading providers of audit, assurance, tax and advisory services, and New Mountain Capital, a leading growth-oriented investment firm with approximately $50 billion in assets under management, today announced the closing of a significant growth investment in Grant Thornton that will accelerate the firm’s business strategy.

Key Points: 
  • Grant Thornton LLP, one of America’s leading providers of audit, assurance, tax and advisory services, and New Mountain Capital, a leading growth-oriented investment firm with approximately $50 billion in assets under management, today announced the closing of a significant growth investment in Grant Thornton that will accelerate the firm’s business strategy.
  • CDPQ and OA Private Capital made minority investments in Grant Thornton alongside New Mountain Capital.
  • Grant Thornton remains part of the Grant Thornton International Limited network of member firms, providing global reach to its clients.
  • CDPQ, a global investment group headquartered in Canada, and OA Private Capital, a family office investment advisory firm located in Michigan, made minority equity investments in Grant Thornton alongside New Mountain Capital.

Sienna Senior Living Inc. Reports Strong First Quarter 2024 Financial Results and Moves Forward with Redevelopment of Long-Term Care Home in Keswick, Ontario

Retrieved on: 
Donnerstag, Mai 9, 2024
OA, LTC, Investment, Safety, Bed, Long-term care, MD, Proxy, Retirement, Environment, Tax, Acquisition, Special, Marketing, NOI, Government, Cryptocurrency

Excluding One-Time & Retroactive Funding of $23,655 related to prior years, same property NOI would be $40,225.

Key Points: 
  • Excluding One-Time & Retroactive Funding of $23,655 related to prior years, same property NOI would be $40,225.
  • Total NOI for the three months ended March 31, 2024 includes $27,010 of One-Time & Retroactive Funding recognized by the Company's LTC segment.
  • Excluding the One-Time & Retroactive Funding relating to prior years, OFFO and AFFO would be $19,364 and $17,994, respectively.
  • Shareholders will be able to listen and participate in the Meeting in real time through a web-based platform at www.virtualshareholdermeeting.com/sia2024 .

Anika Announces CFO Transition

Retrieved on: 
Mittwoch, Mai 8, 2024
OA, CFO, Investment, Elective surgery, Cheryl, Therapy

He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company.

Key Points: 
  • He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company.
  • Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition.
  • “We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability,” said Cheryl Blanchard, Ph.D., Anika’s President and CEO.
  • “I look forward to partnering with Cheryl and the talented Anika team to unlock new opportunities with its significant pipeline of differentiated product lines to deliver sustainable, profitable growth.”
    “I’m very thankful for the opportunity to have been a part of the Anika team,” said Mr. Levitz.

Induced Pluripotent Stem Cell (iPSC) Industry Market Size, Trends, and Forecast Report - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Mai 7, 2024
Health, Stem Cells, OA, Cellular Dynamics International, University, Microsoft Exchange Server, Cell, CRISPR, Safety, Drug development, Osteoarthritis, World Games, MSC, Partnership, Research, CLI, B cell, Application, Disease, Human, Therapy, Patient, COVID-19, Tissue engineering, Graft-versus-host disease, IPSC, Medicine, Kyoto University, 3D bioprinting, Macular degeneration, Regenerative medicine, CDI, Clinical trial, Toxicology, Drug discovery, Personalized medicine, Merck, Thermo Fisher Scientific, Pharmaceutical industry

The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine.
  • Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:
    Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
  • This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development.

Crescent Innovations Offers Breakthrough Osteoarthritis Treatment Technology for Sale, and its impact on Orthopedics

Retrieved on: 
Dienstag, April 30, 2024
OA, Sale, Knee, Hyaluronic acid, Osteoarthritis, Matrix metalloproteinase, ISO, Polyelectrolyte, Confidentiality

WESTFORD, Mass., April 30, 2024 /PRNewswire-PRWeb/ -- Crescent Innovations Inc. announced today the sale of its Poly-gamma-glutamic Acid (PgGA) technology related to osteoarthritis (OA), plus various intellectual property and know-how assets.

Key Points: 
  • WESTFORD, Mass., April 30, 2024 /PRNewswire-PRWeb/ -- Crescent Innovations Inc. announced today the sale of its Poly-gamma-glutamic Acid (PgGA) technology related to osteoarthritis (OA), plus various intellectual property and know-how assets.
  • "Crescent Innovations has shown, both in vitro and in vivo, that...PgGA...reduce[s] MMPs and other inflammatory marker[s] far greater than HA."
  • Al Prescott, President Crescent Innovations Inc.
    PgGA was developed as the next generation of viscosupplements for treat degenerative joint disease.
  • Crescent Innovations has shown, both in vitro and in vivo, that this allows PgGA to reduce MMPs and other inflammatory marker far greater than HA.

Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week

Retrieved on: 
Donnerstag, April 18, 2024
Pain, FDA, Congress, OA, Safety, Biosplice Therapeutics, Osteoarthritis Research Society International, Food, Month, Week, Therapy, Patient, WOMAC, CLK, World Congress, SAN, JSW, Medical device

Preliminary results of OA-07 study, initially reported in November 2023, had demonstrated statistically significant and clinically meaningful improvement in joint structure demonstrated by X-ray results of medial joint space width (medial JSW).

Key Points: 
  • Preliminary results of OA-07 study, initially reported in November 2023, had demonstrated statistically significant and clinically meaningful improvement in joint structure demonstrated by X-ray results of medial joint space width (medial JSW).
  • Biosplice will present its OA-07 results at the Osteoarthritis Research Society International (“OARSI”) World Congress, April 18-21, 2024, in Vienna, Austria.
  • “Patients are desperately seeking a new and safe approach for treating knee osteoarthritis that can provide durable pain relief, improved function, and joint structure benefit,” commented Biosplice Chief Medical Officer, Dr. Yusuf Yazici.
  • The Company observed an unusually high placebo response in this trial compared to published intra-articular OA trials and Biosplice’s prior trials.

Zoetis Announces First Quarter 2024 Results

Retrieved on: 
Donnerstag, Mai 2, 2024
Health, Other Health, Fitness & Nutrition, General Health, Pharmaceutical, Veterinary, Poultry, OA, Summit, Coccidioides immitis, International, Investment, Weather, Fear, Weight gain, Cattle, Levamisole, Animal, Panic, Horse, Growth, Webcast, Transport, Vaccine, Sarolaner, Metritis, Tick, Cat, MFA, Parasitism, Food, Human, Acquisition, Livestock, Mycoplasma bovis, Inc., Dog, EZ, Sheep, Dermatology, RTU

Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2024 and updated its guidance for full year 2024.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2024 and updated its guidance for full year 2024.
  • The company reported revenue of $2.2 billion for the first quarter of 2024, an increase of 10% compared with the first quarter of 2023.
  • On an operational1 basis, revenue for the first quarter of 2024 increased 12% compared with the first quarter of 2023.
  • Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review first quarter 2024 results, discuss financial guidance and respond to questions from financial analysts.

Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies and Better Predict Human Outcomes for Age-Related Diseases

Retrieved on: 
Freitag, April 26, 2024
Founders Fund, FDA, OA, Patient, Horse, Cell, Notifiable disease, Animal, OARSI, Osteoarthritis Research Society International, Infection, Entrepreneurship, Research, Pathology, Artificial intelligence, Disease, Human, Novartis, Therapy, Ageing, Pulmonary fibrosis, Osteoarthritis, Gene, Biology, Drug discovery, Longevity, World Congress, MASH, Heart failure, Pharmaceutical industry

SAN FRANCISCO, April 26, 2024 /PRNewswire/ -- Gordian Biotechnology, an in vivo drug discovery and development company, today announced its platform that enables patient predictive, in vivo screening of hundreds of gene targets for FDA-recognized diseases of aging at a scale never before possible.

Key Points: 
  • Gordian's Osteoarthritis (OA) program has screened hundreds of therapies in horses that acquired OA naturally and advanced dozens of therapies into human ex vivo validation studies.
  • In proof of concept experiments during initial development, Gordian introduced a pooled library of 50 gene therapies into a mouse model of metabolic-associated steatohepatitis (MASH).
  • The therapies were evaluated using the company's proprietary in vivo screening platform, which successfully recapitulated 13 out of 16 clinical outcomes for targets where clinical data exists.
  • Mosaic Screening™ is pooled in vivo screening that tests hundreds of therapies simultaneously in a single sick animal, the Patient Avatar.

TorQuest Partners Announces Strategic Minority Investment by RidgeLake Partners

Retrieved on: 
Dienstag, April 16, 2024
OA, LLP, Torys, Partnership, Kirkland & Ellis, Gibson Dunn, Entrepreneurship, Culture, Partner (business rank), Senior, Growth

TORONTO, April 16, 2024 /PRNewswire/ - TorQuest Partners, a Toronto-based private equity firm founded in 2002 with more than C$5 billion in equity capital under management, is pleased to announce that RidgeLake Partners ("RidgeLake") has made a passive, minority investment in the firm.

Key Points: 
  • TORONTO, April 16, 2024 /PRNewswire/ - TorQuest Partners, a Toronto-based private equity firm founded in 2002 with more than C$5 billion in equity capital under management, is pleased to announce that RidgeLake Partners ("RidgeLake") has made a passive, minority investment in the firm.
  • "RidgeLake's strategic investment is an important part of a broader, long-term succession plan that is presently underway at TorQuest," said Brent Belzberg, Founder and Senior Managing Partner at TorQuest Partners.
  • "RidgeLake affiliates have been investing with TorQuest since 2013 and have been trusted partners throughout the last decade.
  • "We have tremendous respect for the culture and depth of TorQuest and are excited to partner with and assist in the sustained growth of their investment platform," added Michael Lunt, co-head of RidgeLake Partners.

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

Retrieved on: 
Donnerstag, April 11, 2024
OA, Fluticasone, Pain, Patient, Knee, Randomness, OARSI, Osteoarthritis Research Society International, Osteoarthritis, Abstract, TSX, Pharmacokinetics, MRI, Diabetes, World Congress, Pharmaceutical industry

VICTORIA, BC, April 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024.

Key Points: 
  • VICTORIA, BC, April 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024.
  • The meeting is being held in Vienna, Austria from April 18-21, 2024.
  • In combination with our pre-clinical and MRI results, these data suggest a potential best-in-class candidate in terms of managing cartilage health."
  • Poster Title: Pharmacokinetics of EP-104IAR Long-lasting Fluticasone Propionate for Intra Articular Injection in 163 Subjects from SPRINGBOARD, a Phase 2 Study in Knee Osteoarthritis.